ADORA2A and metastatic neoplasm: Patients with high ADORA2A transcript expression in their tumors had longer OS (from the time of advanced/metastatic disease) compared to those with low/moderate ADORA2A expression (HR 0.69 (95% CI, 0.51–0.95), (p = 0.02)) (Figure 3).